Key Summary Points {#FPar1}
==================

There is a paucity of data on the comparative outcomes between trans-femoral and trans-apical accesses in diabetics undergoing TAVR.We found no overall difference among diabetics between TF-TAVR and TA-TAVR as regards to in-hospital mortality.Compared with TA-TAVR, TF-TAVR was associated with lower rates of cardiogenic shock, major bleeding, respiratory complications, and shorter length of stay, at the expense of higher incidence of vascular complications, cardiac tamponade, and permanent pacemaker requirements with TF-TAVR.Subgroup analysis demonstrated that TF-TAVR was associated with higher mortality among complicated diabetics, and lower mortality among non-complicated diabetics, compared with TA-TAVR.

Introduction {#Sec1}
============

Transcatheter aortic valve replacement (TAVR) has become a viable alternative compared with surgical aortic valve replacement (SAVR) in patients with aortic stenosis irrespective of the surgical risk \[[@CR1]--[@CR3]\]. Diabetic patients with aortic stenosis have a different disease profile compared to the general population, with more rapid disease progression and tendency toward left ventricular remodeling and dysfunction \[[@CR4], [@CR5]\]. Studies have proposed TAVR as an appealing option for diabetics, compared with SAVR \[[@CR6]\], yet its outcomes remain affected by the burden of diabetes mellitus (DM) \[[@CR5]\]. Among TAVR patients, DM was demonstrated as an independent predictor of short- and long-term mortality in patients undergoing TAVR \[[@CR7]--[@CR9]\]. DM is a known risk factor for microvascular and macrovascular angiopathies \[[@CR5]\]. Also, diabetics were found to have higher rates of vascular complications post-TAVR \[[@CR10]\]. In this study, we hypothesized that there is an interaction between the access site of TAVR procedures and the outcomes among diabetics undergoing TAVR. To evaluate this hypothesis, we conducted an observational analysis using real-world data to compare outcomes of transapical (TA) versus transfemoral (TF) TAVR procedures among diabetic patients.

Methods {#Sec2}
=======

The data source for this study was the National Inpatient Sample (NIS) database. The NIS is the largest inpatient all-payer healthcare database. Unweighted, the NIS contains data from more than 7 million hospital stays each year, while after appropriate weighting, it estimates more than 35 million hospital stays nationally. The NIS was developed for the Health Care Cost and Utilization Project (HCUP) \[[@CR11]\]. The NIS has been validated internally and externally \[[@CR12], [@CR13]\]. It has been used previously for describing trends and outcomes of various diseases \[[@CR14], [@CR15]\]. This study was exempt from local institutional review board approval, since the NIS contains de-identified data that are publicly available.

We queried the NIS years 2011--2014 to identify hospitalizations that have the International Classification of Diseases, Ninth Edition (ICD-9) procedure codes for TAVR procedures (trans-femoral 35.05 and trans-apical 35.06). We then selected records that carried ICD-9 clinical modification codes for DM (ICD-9-CM codes: 250.00 to 250.33 and 250.40 to 250.93). We excluded cases with missing data on comorbidities, in-hospital mortality, or other study outcomes.

We conducted a propensity-score matched analysis to compare hospitalizations with DM who underwent TF-TAVR to those who underwent TA-TAVR. We reported the trends of TA-TAVR and TF-TAVR in diabetic patients during the study years. The main outcome was all-cause in-hospital mortality. Other outcomes included: cardiogenic shock, acute myocardial infarction (MI), cardiac tamponade, acute stroke, acute kidney injury (AKI), hemodialysis for AKI, major bleeding, requirements of blood transfusion, vascular complications, ventricular arrhythmias, complete heart block, use of mechanical circulatory support devices (MCS), permanent pacemaker insertions, length of hospital stay, and discharges to skilled nursing facilities. Baseline characteristics and clinical outcomes were reported using relevant ICD-9 codes, CCS, and Elixhauser comorbidities as reported by HCUP (Supplemental Table 1).

We conducted a 1:1 propensity score analysis to match TF-TAVR with TA-TAVR, using MatchIt R package. X \[[@CR16]\]. Nearest-neighbor technique was adopted to match each case to a control that is closest in terms of calculated propensity score. The propensity score was calculated from the following clinical variables: age, sex, race, hypothyroidism, fluid/electrolytes abnormalities, hypertension, liver disease, heart failure, history of smoking, chronic kidney disease (CKD), chronic lung disease, peripheral arterial disease (PAD), anemia, pulmonary circulatory disorders, obesity, history of percutaneous coronary intervention (PCI), previous coronary artery bypass grafting (CABG), and prior MI. Prespecified subgroup analyses were conducted for all study outcomes in TF-TAVR versus TA-TAVR in patients with complicated DM compared with those with uncomplicated DM. Complicated DM was defined per DM-related complications including neuropathy, nephropathy, ophthalmopathy, and angiopathies. In the subgroup analysis, to maintain the baseline balance between the TF-TAVR and TA-TAVR groups, only the corresponding matched pairs in a subgroup were selected.

We used the updated weighting samples for national estimates in accordance with HCUP regulations \[[@CR17]\]. We compared categorical values using Chi-square test and continuous variables using Student's *t* test. We reported categorical variables as numbers and percentages, while continuous variables were reported as mean $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \pm $$\end{document}$ standard deviation or median and interquartile range, depending on the skewness of distribution. Breslow--Day test was used to test the homogeneity of the odds ratio. Linear regression analysis was used to evaluate time trend analyses. Effect sizes were expressed using odds ratios (OR) and 95% confidence interval (CI). Associations were considered significant if the *p* value was \< 0.05. We used SPSS software (IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY, USA: IBM Corp Released 2016) and R software for all statistical analysis \[[@CR18]\].

Results {#Sec3}
=======

The study flow sheet is outlined in Fig. [1](#Fig1){ref-type="fig"}. From 2011 to 2014, our search yielded 14,555 diabetics who underwent TAVR. After excluding 12 cases with missing baseline characteristics, a total of 14,543 hospitalizations were included. TF-TAVR was performed in 11,769 (80.9%) of those hospitalizations, while TA-TAVR was performed in 2774 (19.1%) hospitalizations. There was no change in the trend of TF-TAVR or TA-TAVR procedures in diabetics from 2011 to 2014 (*P*~trend~ = 0.60 and 0.41, respectively) (Fig. [2](#Fig2){ref-type="fig"}). Propensity score analysis, the matched cohort included a total of 5437 hospitalizations; 2718 in the TF-TAVR and 2719 in the TA-TAVR groups.Fig. 1Study flow sheetFig. 2Trend of TF-TAVR and TA-TAVR procedures among diabetics

The baseline characteristics of the study population are outlined in Table [1](#Tab1){ref-type="table"}. Before matching, the TF-TAVR group were more likely to be older, females, whites, African Americans, and to have a history of heart failure, prior PCI, CKD, pulmonary circulation disorders, obesity, and anemia. The TA-TAVR group had higher prevalence of Hispanics, Asians, prior CABG, chronic lung disease, and PAD. After matching, the standardized mean differences between both groups in the baseline characteristics were all less than 10% suggesting minimal differences (Supplemental Fig. 1).Table 1Baseline characteristics of unmatched and matched cohortsUnmatched cohortMatched cohort^a^TF-TAVR (*n* = 11,769)\
*N* %TA-TAVR (*n* = 2774)\
*N* %*p* valueTF-TAVR (*n* = 2718)\
*N* %TA-TAVR (*n* = 2719)\
*N* %Age79.5 ± 8.178.2 ± 8.6\< 0.00178.61 ± 8.4878.31 ± 8.6Female sex526844.7%137049.4%\< 0.001128847.4%133048.9%Fluid and electrolyte disorders271323.0%107438.7%\< 0.00190833.4%103438.0%Hypothyroidism233119.8%56820.5%0.42857921.3%56320.7%Liver disease4533.8%843.0%0.040702.6%843.1%*[Race]{.ul}*White934479.4%209775.6%\< 0.001216479.6%208276.6%Black5694.8%953.4%0.001903.3%953.5%Hispanic4954.2%1846.6%\< 0.0011204.4%1796.6%Asian Pacific Islander1401.2%552.0%0.001351.3%552.0%Native AmericanNRNR351.3%\< 0.001NRNRNRNROther races3973.4%893.2%0.721742.7%843.1%Hypertension986583.8%233684.2%0.605221281.4%228183.9%Complicated diabetes197716.8%51818.7%0.01845316.7%50318.5%History of heart failure143012.1%1756.3%\< 0.0011505.5%1756.4%History of smoking321427.3%80228.9%0.08976928.3%78228.7%History of PCI254721.6%50718.3%\< 0.00150818.7%50218.5%History of CABG311626.5%79228.6%0.02774627.5%76228.0%Prior MI187215.9%40414.6%0.08239014.3%39914.7%Chronic kidney disease503742.8%11840.3%0.017112941.5%109840.4%Chronic lung disease418335.5%104437.6%0.039110340.6%101937.5%Pulmonary circulation disorder5004.2%451.6%\< 0.001451.7%451.7%Peripheral artery disease330028.0%109139.3%\< 0.00199736.7%105138.6%Obesity271823.1%56020.2%0.00152219.2%55520.4%Anemia340929.0%73826.6%0.01376628.2%72326.6%*SD* standard deviation, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *MI* myocardial infarction, *NR* not reportable; Per HCUP regulations, frequencies fewer than 11 should not be reported^a^After matching, the standardized differences between both groups in all matched variables were less than 10%, suggesting minimal differences

After matching, in-hospital mortality was not different between TF-TAVR and TA-TAVR (3.5 vs. 4.4%, OR 0.79; 95% CI 0.60--1.04, *p* = 0.11). TF-TAVR was associated with lower rates of cardiogenic shock (2.7 vs. 4.7%, OR 0.61; 95% CI 0.46--0.82, *p* = 0.02), utilization of MCS (2.0 vs. 2.9%, OR 0.67; 95% CI 0.47--0.95, *p* = 0.03), AKI (17.8 vs. 26.5%, OR 0.60; 95% CI 0.53--0.68, *p* \< 0.001), major bleeding (35.8 vs. 40.7%, OR 0.82; 95% CI 0.73--0.91, *p* \< 0.001), blood transfusions (21.4 vs. 31.3%, OR 0.60; 95% CI 0.53--0.68, *p* \< 0.001), respiratory complications (1.1 vs. 4.4%, OR 0.24; 95% CI 0.16--0.36, *p* \< 0.001), discharge to skilled facilities (26.1 vs. 39.3%, OR 0.55; 95% CI 0.49--0.61, *p* \< 0.001), and shorter mean length of stay (7.8 ± 6.8 vs. 9.9 ± 7.4 days, *p* \< 0.001) compared with TA-TAVR. However, TF-TAVR was associated with a higher rate of vascular complications (2.9 vs. 0.9%, OR 3.4; 95% CI 2.1--5.3, *p* \< 0.001), cardiac tamponade (0.5 vs. 0.0%, OR 0.1.005; 95% CI 1.002--1.008, *p* \< 0.001), complete heart block (10.8 vs. 7.7%, OR 1.45; 95% CI 1.20--1.75, *p* \< 0.001) and permanent pacemaker insertion (11.8 vs. 8.3%, OR 1.49; 95% CI 1.25--1.78, *p* \< 0.001). There was no difference between both groups in acute stroke (1.8 vs. 2.2%, OR 0.83; 95% CI 0.57--1.2, *p* = 0.39), acute MI (2.6 vs. 2.8%, OR 0.93; 95% CI 0.67--1.30, *p* = 0.74) hemodialysis (2.0 vs. 2.2%, OR 0.92; 95% CI 0.63--1.33, *p* = 0.71) and ventricular arrhythmias (4.9 vs. 4.2%, OR 1.19; 95% CI 0.92--1.53, *p* = 0.19) (Fig. [3](#Fig3){ref-type="fig"}) (Table [2](#Tab2){ref-type="table"}).Fig. 3Comparative outcomes between TF-TAVR and TA-TAVR in the matched cohort. *AKI* acute kidney injuryTable 2In-hospital outcomes for TF-TAVR compared with TA-TAVR in the matched cohortOutcomeTF-TAVR (*n* = 2718)\
*N* %TA-TAVR (*n* = 2719)\
*N* %*p* valueOR95% confidence intervalMortality953.5%1194.4%0.1080.7910.601--1.042Cardiogenic shock742.7%1194.4%0.0010.6120.455--0.822Vascular complications792.9%240.9%0.0003.3632.123--5.327Acute stroke501.8%602.2%0.3860.8310.569--1.214TIA/Stroke652.4%702.6%0.7280.9280.659--1.306Acute kidney injury48317.8%72026.5%\< 0.0010.6000.527--0.683Acute myocardial infarction702.6%752.8%0.7360.9320.670--1.297Cardiac tamponade140.5%NRNR\< 0.0011.0051.002--1.008MCS542.0%802.9%0.0280.6690.472--0.949Major bleeding97435.8%110640.7%\< 0.0010.8150.730--0.909Blood transfusion58121.4%85031.3%\< 0.0010.5980.529--0.676Hemodialysis552.0%602.2%0.7060.9160.633--1.325Complete heart block29410.8%2107.7%\< 0.0011.4501.204--1.745Ventricular arrhythmias1344.9%1144.2%0.1941.1850.918--1.531PPM32211.8%2258.3%\< 0.0011.4901.245--1.782Respiratory complications301.1%1204.4%\< 0.0010.2420.161--0.362PCI802.9%802.9%1.0001.0010.731--1.371Discharge to SNF71026.1%106839.3%\< 0.0010.5470.487--0.614Length of stay (mean ± SD)7.78 ± 6.779.87 ± 7.43\< 0.001*TIA* transient ischemic attack, *MCS* mechanical circulatory support device, *PPM* permanent pacemaker insertion, *PCI* percutaneous coronary intervention, *SNF* skilled nursing facility, *NR* not reportable; Per HCUP regulations, frequencies fewer than 11 should not be reported

On subgroup analysis, TF-TAVR in patients with complicated diabetes was associated with higher rate of in-hospital mortality compared with TA-TAVR (7.7 vs. 2.0%, OR 4.13; 95% CI 2.02--8.44, *p* \< 0.001), while in non-complicated diabetics TF-TAVR was associated with lower in-hospital mortality compared with TA-TAVR (2.7 vs. 4.9%, OR 0.53; 95% CI 0.38--0.73, *p* \< 0.001); *P*~interaction~ \< 0.001. Results of subgroup analysis for the other study outcomes are presented in Table [3](#Tab3){ref-type="table"}. Compared with non-complicated diabetics, TF-TAVR among complicated diabetics was associated with higher rate of acute stroke (*P*~interaction~ = 0.05), AKI (*P*~interaction~ = 0.05), hemodialysis (*P*~interaction~ = 0.05), blood transfusions (*P*~interaction~ = 0.03), percutaneous coronary intervention (*P*~interaction~ = 0.02), and respiratory complications (*P*~interaction~ \< 0.001).Table 3Subgroup analysis according to the status of diabetes for in-hospital complications for TF-TAVR versus TA-TAVROutcomeUncomplicated diabetesComplicated diabetes*P*~interaction~TF-TAVR (*n* = 1268)\
*N* %TA-TAVR (*n* = 1189)\
*N* %OR95% CITF-TAVR (*n* = 254)\
*N* %TA-TAVR (*n* = 281)\
*N* %OR95% CICardiac arrest393.1%554.6%0.6540.4310.994187.1%165.7%1.2630.6302.5330.110Cardiogenic shock3434484.0%0.6550.4191.024NRNR134.6%0.7570.3181.8030.770Vascular complications393.1%141.2%2.6631.4394.930NRNRNRNR1.0241.0051.0440.208Acute stroke211.7%292.4%0.6740.3821.188NRNRNRNR3.3750.67516.8750.048TIA/Stroke292.3%352.9%0.7720.4691.271NRNRNRNR3.3750.67516.8750.068AKI19315.2%29324.6%0.5490.4490.6727830.7%9834.9%0.8280.5761.1890.052AMI262.1%252.1%0.9750.5601.698155.9%165.7%1.0390.5032.1480.890Cardiac tamponadeNRNRNRNR1.0071.0021.012NRNRNRNRNA0.325MCS282.2%413.4%0.6320.3881.029NRNRNRNR1.6670.27610.0600.325Major bleeding44735.3%48440.7%0.7930.6740.93410039.4%10938.8%1.0250.7241.4510.191Blood transfusion25420.0%37431.5%0.5460.4540.6567328.7%8931.7%0.8700.6011.2600.027Hemodialysis201.6%262.2%0.7170.3981.291124.7%NRNR2.2730.8406.1480.046Complete heart block14211.2%998.3%1.3881.0601.8183011.8%196.8%1.8471.0123.3710.395PPM15011.8%978.2%1.5101.1551.9763513.8%2810.0%1.4440.8512.4510.882Ventricular arrhythmias635.0%453.8%1.3290.8991.965124.7%145.0%0.9460.4292.0850.448Respiratory complicationsNRNR595.0%0.1680.0880.321NRNRNRNR2.2420.5559.059\< 0.001PCI241.9%332.8%0.6760.3971.150166.3%NRNR2.2940.9655.4560.016Discharges to facilities32525.6%48140.5%0.5070.4270.6027529.5%10637.7%0.6920.4820.9930.126*TIA* transient ischemic attack, *AKI* acute kidney injury, *AMI* acute myocardial infarction, *PPM* permanent pacemaker insertion, *PCI* percutaneous coronary intervention, *NR* not reportable; Per HCUP regulations, frequencies fewer than 11 should not be reported

Discussion {#Sec4}
==========

In this observational analysis including 14,543 hospitalizations, we sought to evaluate the comparative outcomes between trans-femoral and trans-apical accesses in diabetics undergoing TAVR. After propensity matching, we found no overall difference among diabetics between TF-TAVR and TA-TAVR as regards to in-hospital mortality. After matching, TF-TAVR was associated with lower rates of cardiogenic shock, utilization of MCS, AKI, major bleeding, blood transfusions, respiratory complications, and shorter length of stay compared with TA-TAVR. On the other side, TF-TAVR was associated with higher incidence of vascular complications, cardiac tamponade, complete heart block, and permanent pacemaker requirements. No difference was observed between both groups in the rates of acute stroke, acute MI, hemodialysis, and ventricular arrhythmias. Subgroup analysis showed that among complicated diabetics, TF-TAVR was associated with higher rates of in-hospital mortality, acute stroke, AKI, hemodialysis, PCI, and respiratory complications, compared with non-complicated diabetics.

Diabetes is a traditional risk factor that has been established to confer additional morbidity and mortality to various surgical and transcatheter procedures \[[@CR19], [@CR20]\]. DM is included as a risk factor in the Society of Thoracic Surgeons Risk Score and EuroSCORE II, both of which are validated tools in predicting 30-day mortality after cardiac surgery \[[@CR19], [@CR20]\]. Specifically, studies have suggested an interaction for diabetes with clinical outcomes after TAVR, with reports of unfavorable outcomes associating diabetics undergoing TAVR at short and long term \[[@CR7]--[@CR9]\]. Abramowitz et al. conducted an analysis using the Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/TVT) Registry, including 47,643 patients. Their analysis showed that diabetes was a significant predictor of 1-year mortality \[[@CR5]\]. Also, in the Ibero-American registry including 1220 TAVRs, diabetes was found to be an independent predictor of long-term mortality \[[@CR7]\]. However, the impact of access site on the interaction between diabetes and TAVR procedures has not been adequately characterized.

Multiple studies have compared TF-TAVR and TA-TAVR in all comers with results suggesting favorable short- and long-term mortality with TF-TAVR. Kumar et al. conducted an analysis using the NIS database to compare TF-TAVR and TA-TAVR in all comers. Their results showed that TF-TAVR was associated with lower rates of in-hospital mortality compared with TA-TAVR \[[@CR21]\]. Results from other registries showed similar survival benefit with TF-TAVR \[[@CR22], [@CR23]\].

Unlike the studies on all-comers, our analysis showed no significant difference between trans-femoral and trans-apical accesses in diabetics undergoing TAVR. This lack of difference might be attributed to higher incidences of vascular complications and bradyarrhythmia complications, which might have neutralized the overall benefits observed with TF-TAVR in studies on all-comers. In our analysis, we found a threefold higher rates of vascular complications among diabetics who underwent TF-TAVR compared with TA-TAVR. Prior studies have demonstrated that diabetes is associated with higher vascular complications among patients undergoing TF-TAVR \[[@CR10], [@CR24]\]. In a pooled analysis from the Placement of Aortic Transcatheter Valve (PARTNER) Trial, major vascular complications were evaluated in 419 patients \[[@CR10]\]. Insulin-dependent diabetics had more than threefold higher rates of vascular complications compared with non-diabetics \[[@CR10]\].

Consistent with other studies, TF-TAVR had more favorable hemodynamic outcomes; with less rates of cardiogenic shock, use of MCS, AKI, as well as less respiratory complications \[[@CR25], [@CR26]\]. We found no difference between TF-TAVR and TA-TAVR in acute stroke. The theoretical benefit for TA-TAVR by avoiding manipulation of the aorta and direct valve implantation, did not translate to lower stroke risk in many clinical studies, similar to our results \[[@CR25], [@CR27]\].

In our study, subgroup analysis identified significant interaction between the status of diabetes (i.e., complicated or not) with mortality outcomes in TF-TAVR compared with TA-TAVR. Such interaction seemed to be driven by higher rates of acute stroke, AKI, hemodialysis, and PCI for TF-TAVR among complicated diabetics. Patients with complicated diabetes are mostly insulin-dependent and are likely to have diabetes-related complications. Other reports have suggested an interaction between the status of diabetes and outcomes after TAVR. In the analysis by Abramowitz et al., insulin-treated diabetes was a stronger predictor of 1-year mortality compared with non-insulin-treated diabetes among TAVR patients \[[@CR5]\], driven by higher requirements of hemodialysis, MI, and heart failure readmissions \[[@CR5]\]. Data from an Italian registry showed that being insulin-treated DM, but not orally treated DM, was an independent predictor of mortality and MI at 1-year follow-up \[[@CR9]\]. Data from a single-center study also showed the same results with worse mid-term mortality after TAVR in insulin-treated diabetics \[[@CR28]\].

Compared to all-comers undergoing TAVR, the relatively worse outcomes with DM, in particularly complicated DM, could be related to the pathophysiological changes associating DM. Diabetic patients with severe aortic stenosis have a different profile compared with the general population. They have more accelerated progression of AS, left ventricular remodeling, and reduced systolic function compared with non-diabetic AS patients \[[@CR4], [@CR5]\]. The worse outcomes with advanced DM are attributed to diabetes-related complications including renal disease and vasculopathies at multiple vascular beds with more propensity for cardiac, cerebrovascular, and peripheral vascular complications. Increased post-operative inflammation and oxidative stress among diabetics is also a contributing factor to worse post-procedural outcomes \[[@CR29]\].

This current analysis is the first analysis to date exploring the impact of DM on access site for TAVRs. The lack of mortality benefit with TF-TAVR versus TA-TAVR in diabetics compared with studies on all-comers is an important finding. Patients with complicated DM might have higher in-hospital mortality with TF-TAVR compared with TA-TAVR. The results of our subgroup analysis highlight the importance of careful patient selection and individualized decisions on access sites for TAVR in diabetic patients. Further studies are warranted to explore the outcomes of alternative access sites for TAVR in diabetics, in particular complicated diabetes.

This analysis has several limitations. The NIS is an administrative database, which is liable to coding and documentation errors. It is also a time-discrete database, with no available data on long-term outcomes. Given the timeframe of our study, the evaluated TAVR procedures were mostly using first-generation TAVR valves. Newer generations of TAVR valves have smaller vascular profiles and might carry less vascular complications. Also, the use of TA-TAVR has decreased and has lower incidence than that reported in our study. Other relevant information could not be retrievable from this dataset including data on imaging tests, types of TAVR valves utilized, or laboratory results. Being an observational analysis, there is potential for selection bias. However, we conducted a propensity match analysis to reduce allocation biases. Nevertheless, the possibility of unmeasured confounders exists. Despite the aforementioned limitations, the current study contributes to the literature regarding the impact of diabetes on outcomes of TAVR procedures.

Conclusions {#Sec5}
===========

This observational analysis of a large national database showed no difference in in-hospital mortality between TF-TAVR and TA-TAVR among diabetic patients. Among complicated diabetics, TF-TAVR might be associated with unfavorable outcomes compared with TA-TAVR. Studies exploring the optimal access for TAVR among diabetics are still required.

Electronic supplementary material
=================================

 {#Sec6}

Below is the link to the electronic supplementary material. Supplementary material 1 (TIFF 1205 kb)Supplementary material 2 (DOCX 14 kb)

**Enhanced Digital Features**

To view enhanced digital features for this article go to 10.6084/m9.figshare.10008341.

Funding {#FPar2}
=======

No funding or sponsorship was received for this study or publication of this article.

Authorship {#FPar3}
==========

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Prior Presentation {#FPar4}
==================

An abstract for this manuscript was presented at the Society for Cardiovascular Angiography & Interventions (SCAI) annual meeting May 2019, Las Vegas, NV, USA.

Disclosures {#FPar5}
===========

Ayman Elbadawi, Ahmed H. Mohamed, Mohamed A. Omer, Islam Y. Elgendy, Ahmed Abuzaid, Gbolahan Ogunbayo, Michael Megaly, Hend I Shahin, Karim Mahmoud, Ken Fujise, and Syed Gilani have nothing to disclose.

Compliance with Ethics Guidelines {#FPar6}
=================================

This study was exempt from local institutional review board, since the NIS contains de-identified data that are publicly available.

Data Availability {#FPar7}
=================

All data generated or analyzed during this study are included in this published article/as supplementary information files.

Open Access {#d30e3241}
===========

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
